Integrating network analysis and experimental validation to reveal the ferroptosis-associated mechanism of acteoside in the treatment of diabetic nephropathy
In summary, this study provides preclinical evidence that ACT ameliorates DN through ferroptosis inhibition, positioning it as a novel therapeutic candidate for DN treatment.
Authors
- Zheng Luo (ORCID: https://orcid.org/0000-0001-5168-4674)
- Weijing Liu (ORCID: https://orcid.org/0000-0003-0593-5983)
- Hongmei Lü (ORCID: https://orcid.org/0000-0002-8103-6552)
- Yu Ma (ORCID: https://orcid.org/0000-0002-6300-7280)
- Yi Kang (ORCID: https://orcid.org/0000-0002-4282-1013)
- Yaoxian Wang (ORCID: https://orcid.org/0000-0002-1927-9529)
- Shujiao Zhang
- Xinghua Zhang (ORCID: https://orcid.org/0000-0003-0174-5410)
- Jingyi Tang (ORCID: https://orcid.org/0000-0002-8754-5809)
- Yuanyuan Deng (ORCID: https://orcid.org/0000-0003-1081-1379)
Institutions
- Beijing University of Chinese Medicine (CN)
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
- First Affiliated Hospital of Henan University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.3389/fphar.2025.1660227
- Citations
- 2
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities